Neogen (NEOG) vs TransMedics Group (TMDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Neogen (NEOG) has outperformed TransMedics Group (TMDX) over the past year, gaining 101.2% versus a loss of 33.1%. Over five years, TMDX leads with a +197.6% price change compared with -71.5% for NEOG. TransMedics Group is the larger company by market cap ($2.74 billion vs $2.55 billion), about 1.1 times the size.
On valuation, Neogen trades at a lower forward P/E (30.8x vs 35.0x for TransMedics Group). TransMedics Group converts more of its revenue into profit, with a net margin of 31.4% versus -0.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NEOG | TMDX |
|---|---|---|
| Share price | $11.71 | $79.00 |
| Market cap | $2.55B | $2.74B |
| 1-day change | +0.26% | -2.55% |
| YTD return | +67.53% | -35.06% |
| 1-year return | +101.20% | -33.08% |
| 5-year return | -71.47% | +197.55% |
| P/E ratio (TTM) | — | 20.47 |
| Forward P/E | 30.82 | 35.05 |
| EPS (TTM) | $-0.26 | $3.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $870.40M | $605.49M |
| Revenue growth (YoY) | -2.72% | +37.13% |
| Net income (latest FY) | $-7.90M | $190.29M |
| Gross margin | 46.93% | 59.92% |
| Operating margin | -2.48% | 17.93% |
| Net margin | -0.91% | 31.43% |
| 52-week high | $14.26 | $156.00 |
| 52-week low | $5.37 | $60.11 |
| Distance from 52-week high | -17.88% | -49.36% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +19.56% | +26.35% |
| Average volume | 3.14M | 820.41K |
| Shares outstanding | 218.11M | 34.68M |
| Employees | 2,636 | 898 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NEOG has outperformed TMDX by 134.3 percentage points over the past year.
- TransMedics Group is more profitable, keeping 31.4 cents of every revenue dollar as net income versus -0.9 cents for Neogen.
- TransMedics Group grew revenue faster in its latest fiscal year (+37.13% vs -2.72%).
About Neogen
NEOG stock →Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,636 employees
About TransMedics Group
TMDX stock →TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 898 employees
NEOG vs TMDX FAQ
Which is bigger, Neogen or TransMedics Group?
TransMedics Group (TMDX) is larger, with a market capitalization of $2.74B compared with $2.55B for Neogen (NEOG).
Which stock has performed better over the past year, NEOG or TMDX?
NEOG returned +101.20% over the past 12 months, compared with -33.08% for TMDX (price return, excluding dividends). Past performance does not predict future results.
Are Neogen and TransMedics Group in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: In Vitro & In Vivo Diagnostic Substances for Neogen and Biotechnology: Electromedical & Electrotherapeutic Apparatus for TransMedics Group.